Molecular Formula | C19H24ClNO |
Molar Mass | 317.86 |
Melting Point | 165 - 168°C |
Solubility | DMSO : 25 mg/mL (78.65 mM; Need ultrasonic) |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | -20°C Freezer, Under inert atmosphere |
In vivo study | The pre-administration of Blarcamesine (ANAVEX2-73) leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ 25-35 -induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser 9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ 25-35 -induced increase in Aβ 1-42 content, with a significant effect at the highest dose tested. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.146 ml | 15.731 ml | 31.461 ml |
5 mM | 0.629 ml | 3.146 ml | 6.292 ml |
10 mM | 0.315 ml | 1.573 ml | 3.146 ml |
5 mM | 0.063 ml | 0.315 ml | 0.629 ml |
biological activity | Anavex 2-73 (Blarcamesine, AVex-73, AE-37) is an amino tetrahydrofuran derivative, it is also an agonist of a mixed muscarinic and sigma-1/p1 Receptor with an IC50 value of 0.86 μm. |
Target | Value |
muscarinic () | |
sigma-1 receptor (Cell-free assay) | 0.86 μM |